1. A Multi-center, Dose-escalation Study of Human type I Pancreatic Elastase (PRT-201) Administered after Arteriovenous Fistula Creation
- Author
-
Eric K. Peden, Jeffrey H. Lawson, Andrew T. Blair, Mahmoud El-Khatib, Matthew T. Menard, Marianne Magill, Bradley S. Dixon, Laura M. Dember, Prabir Roy-Chaudhury, Steven K. Burke, F. Nicholas Franano, Marc H. Glickman, Pamela N. Gustafson, and David B. Leeser
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Arteriovenous fistula ,Human type ,Drug Administration Schedule ,law.invention ,Upper Extremity ,Arteriovenous Shunt, Surgical ,Double-Blind Method ,Randomized controlled trial ,Renal Dialysis ,Risk Factors ,law ,Dose escalation ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Pancreatic elastase ,Vascular Patency ,Aged ,Proportional Hazards Models ,Analysis of Variance ,Pancreatic Elastase ,business.industry ,Graft Occlusion, Vascular ,PRT-201 ,Thrombosis ,Middle Aged ,medicine.disease ,United States ,Surgery ,Clinical trial ,Treatment Outcome ,Multicenter study ,Nephrology ,Original Article ,Female ,Carrier Proteins ,business - Abstract
Purpose To explore the safety and efficacy of PRT-201. Methods Randomized, double-blind, placebo-controlled, single-dose escalation study of PRT-201 (0.0033 to 9 mg) applied after arteriovenous fistula (AVF) creation. Participants were followed for one year. The primary outcome measure was safety. Efficacy measures were the proportion with intra-operative increases in AVF outflow vein diameter or blood flow ≥25% (primary), changes in outflow vein diameter and blood flow, AVF maturation and lumen stenosis by ultrasound criteria and AVF patency. Results The adverse events in the PRT-201 group (n=45) were similar to those in the placebo group (n=21). There were no differences in the proportion with ≥25% increase in vein diameter or blood flow, successful maturation or lumen stenosis. There was no statistically significant difference in primary patency between the dose groups (placebo n=21, Low Dose n=16, Medium Dose n=17 and High Dose n=12). In a subgroup analysis that excluded three participants with early surgical failures, the hazard ratio (HR) for primary patency loss of Low Dose compared with placebo was 0.38 (95% CI 0.10-1.41, P=0.15). In a Cox model, Low Dose (HR 0.27, 95% CI 0.04-0.79, P=0.09), white race (HR 0.17, 95% CI 0.03-0.79, P=0.02), and age Conclusions PRT-201 was not different from placebo for safety or efficacy measures. There was a suggestion for improved AVF primary patency with Low Dose PRT-201 that is now being studied in a larger clinical trial.
- Published
- 2012
- Full Text
- View/download PDF